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The implantable cardioverter defibrillator (ICD) has had an
enormous impact on the treatment of patients with life-
threatening ventricular arrhythmias. It has been shown not
only to be effective in reducing mortality in patients who
have survived a potentially life-threatening ventricular ar-
rhythmia (1) but also to improve outcomes when used as
primary prevention for sudden cardiac death in patients with
ischemic cardiomyopathies (2–4). However, an ongoing
problem with ICD therapy is recurrent shocks that occur in
some patients. Inappropriate shocks can occur because of
problems with the defibrillator lead itself or from supraven-
tricular tachyarrhythmias, most commonly atrial fibrillation
(AF). In addition, patients can receive recurrent appropriate
shocks for the ventricular arrhythmias for which the ICD
was originally implanted. Although such shocks can be life
saving, they can be painful and emotionally traumatic for
the patient, particularly if they are frequent.
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Antitachycardia pacing is often effective in terminating
ventricular tachycardia (VT), even when programmed em-
pirically (5). Particularly for slower, more stable episodes of
VT, antitachycardia pacing can terminate all or most epi-
sodes of VT, often with the patient unaware that the
arrhythmia even occurred. Recently, antitachycardia pacing
has also been shown to be effective for more rapid, hemo-
dynamically unstable episodes of VT (6). However, there
are patients who experience frequent shocks for polymor-
phic VT or ventricular fibrillation (VF) for which antitachy-
cardia pacing is ineffective. In addition, antitachycardia
pacing may be ineffective for the termination of VT or only
partially effective so that patients may continue to experi-
ence recurrent ICD shocks even though the majority of
arrhythmia episodes may be terminated with pacing.
Another option for control of frequent shocks from ICDs
is radiofrequency catheter ablation. Although catheter ab-
lation of VT is effective in many patients (7), the procedure
is long and technically demanding. There are often multiple
tachycardias present, which can make mapping and ablation
of individual tachycardias difficult. Hemodynamically un-
stable arrhythmias create challenges as well, in that patients
cannot tolerate the arrhythmias for any length of time, often
making point-by-point mapping impossible. Although
techniques to ablate the substrate for VT by mapping
regions of unexcitable scar and creating ablation lines across
potential areas where reentrant circuits can develop are
promising, these procedures can still realistically be per-
formed only in relatively small numbers of experienced
centers. For all these reasons, adjunctive antiarrhythmic
drug therapy is necessary in many patients with implanted
defibrillators for control of recurrent ventricular tachyar-
rhythmias.
It has been estimated that 20% to 50% of patients with
ICDs require adjuvant antiarrhythmic drug therapy (8). In
the Antiarrhythmics Versus Implantable Defibrillators
(AVID) trial, 18% of patients in the ICD arm received
antiarrhythmic drugs in follow-up (9). Because antiarrhyth-
mic drug treatment in the trial was considered a crossover,
this percentage should be considered an absolute minimum
of the number of patients with ICDs who are likely to
require antiarrhythmic drugs. The AVID trial included only
patients with a history of life-threatening ventricular ar-
rhythmias. With the increasing use of ICDs for primary
prevention of sudden cardiac death, it might be presumed
that the frequency of shocks in follow-up will be lower.
However, supraventricular tachyarrhythmias are frequent in
patients with serious structural heart disease for whom
prophylactic ICDs are considered, making it likely that a
significant proportion of patients will still require adjuvant
drug therapy for arrhythmias.
Amiodarone is the most commonly used drug for the
prevention of shocks in implanted defibrillators. One of the
more important reasons for its frequent use when drug
therapy is necessary is the fact that amiodarone is safe to use
in patients with poor ventricular function (10). Although
it is widely considered to be an effective drug for prophylaxis
against frequent shocks, there are surprisingly few studies
that demonstrate this. In the Cardiac Arrest in Seattle:
Conventional Versus Amiodarone Drug Evaluation
(CASCADE) study (11), patients with ICDs who received
amiodarone experienced fewer appropriate shocks from
their defibrillators than patients treated with conventional
antiarrhythmic drugs. However, it cannot be determined
from this study whether the amiodarone actually reduced
the number of shocks or the conventional antiarrhythmic
drugs were proarrhythmic.
Although amiodarone is currently the most commonly
prescribed drug for treatment of frequent shocks in patients
with ICDs, patients often develop serious side effects such
as pulmonary fibrosis, necessitating discontinuation of the
drug. There are then few other options for treatment,
particularly in patients with symptomatic heart failure.
Class I antiarrhythmic drugs may be proarrhythmic and
are not as effective as amiodarone (11). A recent study
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investigated the use of dofetilide, a newer class III antiar-
rhythmic drug, for the prevention of shocks from implanted
defibrillators. In a double-blind, placebo-controlled study in
patients with ICDs, dofetilide did not affect the time to first
ICD intervention (antitachycardia pacing or shock) for VT
or VF (12). This finding is unfortunate, inasmuch as
dofetilide is the only drug aside from amiodarone that has
been demonstrated not to affect survival adversely in pa-
tients with serious structural heart disease (13).
Sotalol, however, which is another class III antiarrhyth-
mic drug, has been found effective in preventing shocks
from ICDs. In a prospective, randomized study, patients
who received ICDs for documented ventricular arrhythmias
were given sotalol or placebo and followed up for 12 months
(14). Sotalol reduced the risk of a first shock for any reason
or death by 48% compared with placebo (p 0.001). At one
year, 66% of patients receiving sotalol versus 46% of patients
receiving placebo were free of the primary end point. The
frequency of shocks was reduced from 3.9  10.6/year with
placebo to 1.4  3.5/year with sotalol. The drug was
effective in reducing the frequency of both appropriate and
inappropriate shocks. Sotalol has thus been shown to be an
effective drug for prophylaxis against recurrent arrhythmias
in patients with ICDs. However, in the study described
earlier, 66% of the patients had ejection fractions 30%.
Many of the patients who are most in need of antiarrhyth-
mic drugs to prevent shocks from ICDs have poor ventric-
ular function and cannot tolerate the negative inotropic
effects of sotalol. If these patients have intolerable side
effects from amiodarone or the drug has been ineffective,
there are really no other good options for treatment.
Atrioventricular nodal blocking drugs can be used to prevent
detection and treatment of supraventricular tachyarrhyth-
mias, but other drugs for the prevention of ventricular
arrhythmias are sorely needed.
Azimilide is a class III antiarrhythmic drug under inves-
tigation for the treatment of supraventricular and ventricular
tachyarrhythmias. It blocks both the rapid (IKr) and the
slow (IKs) components of the delayed rectifier cardiac
potassium channel. It has been demonstrated to be effective
in the treatment of AF (15). In this issue of the Journal, a
pilot study of the efficacy of azimilide in reducing the
frequency of ventricular arrhythmias in patients with ICDs
is reported (16). Patients eligible for the study either had
both an implanted defibrillator and at least one shock over
the preceding year or had documented VT or VF and
inducible VT or VF with noninvasive programmed stimu-
lation through the ICD. There were 172 patients who were
randomized to treatment with either placebo or one of three
doses of azimilide (35, 75, or 125 mg/day) and followed up
for 12 months. The patients enrolled in the study had a high
frequency of ICD therapies. There were 2,011 appropriate
therapies, with a mean of 18  50 per patient and a median
of 4. There were 358 appropriate shocks, with a mean of
4  5 per patient and a median of 2. The mean ejection
fraction was approximately 31%, with 62% of the patients
having an ejection fraction 35%.
The frequency of appropriate shocks and antitachycardia
pacing was significantly decreased in patients who received
an active drug, with efficacy seen at all three dose levels.
Azimilide reduced the frequency of appropriate ICD ther-
apies by 69% compared with placebo (hazard ratio 0.31, p
0.0001). Importantly, azimilide was well tolerated and did
not affect the ejection fraction or defibrillation threshold.
The fact that ICD therapies were reduced at all three dose
levels is interesting in light of the fact that azimilide has
been shown to be effective for the prevention of AF only at
doses of 100 or 125 mg/day (15). If the efficacy of azimilide
at relatively low doses can be confirmed in a larger study, it
would clearly be an advantage in minimizing the risk of side
effects.
There were few adverse events reported. Only two pa-
tients had torsades de pointes, an important observation
with a drug that can prolong the QT interval. Possible
proarrhythmia, defined as new VT or an increased fre-
quency of VT, was equally common in the placebo group
when compared with all three dose groups.
Although this study was a pilot study, the observation
that azimilide significantly reduced the frequency of ICD
therapies in a patient population with a high incidence of
recurrent ventricular arrhythmias is an important one. New
antiarrhythmic drugs for reducing the frequency of ICD
therapies are crucially needed for many reasons. Shocks
from ICDs are uncomfortable for patients and have a
negative impact on quality of life. In addition, frequent
episodes of VT or VF can adversely affect cardiac function,
whereas frequent shocks can affect battery longevity in
ICDs. The results of this pilot study are intriguing but need
to be confirmed in a larger patient cohort. Such a study, the
Shock Inhibition with Azimilide (SHIELD) study, is cur-
rently in progress to confirm the results of the pilot study. If
the favorable effect of azimilide on arrhythmic events in
patients with ICDs can be confirmed, the availability of a
new drug to manage these vexing clinical problems will be
most welcome.
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